Clinical Trial Update: A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years [Phase 3]

View source ↗

Summary

Pfizer completed a global Phase 3 safety study of a 120 mcg rLP2086 vaccine in adolescents and young adults (ages 10-25); results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease
• Meningococcal Meningitis

Drugs mentioned

• rLP2086 vaccine

Snippet

Sponsor: Pfizer | Conditions: Meningitis, Meningococcal | Phase 3 | Status: COMPLETED | Results posted: 2015-03-11